Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter…
288,450€
-0,09%
Echtzeit-Aktienkurs Penumbra Inc.
Bid:
Ask:
Nachrichten zur Penumbra Inc. Aktie
Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of +5.36% and +6.74%, respectively, for the quarter ended December 2025. Do the…
Boston Scientific (BSX) Earnings Transcript
Image source: The Motley Fool.DATEWednesday, February 4, 2026, 8 a.m. ETCALL PARTICIPANTSChairman and Chief Executive Officer — Michael F. MahoneyExecutive…
Boston Scientific to buy Penumbra in deal valued at $14.5 billion
Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.…
Boston Scientific to acquire Penumbra in $14.5B deal
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock...…
Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Penumbra (PEN) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, November 5, 2025, at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Adam ElsesserChief Financial Officer…
Earnings call transcript: Penumbra Inc. beats Q2 2025 estimates By Investing.com
Earnings call transcript: Penumbra Inc. beats Q2 2025 estimates…
Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended June 2025, but…
Penumbra CEO Adam Elsesser sells $3.7m in shares By Investing.com
Penumbra CEO Adam Elsesser sells $3.7m in shares…
Penumbra CEO Elsesser sells $3.89m in shares By Investing.com
Penumbra CEO Elsesser sells $3.89m in shares…
Penumbra - Medizintechnikkonzern profitiert von Nachzieheffekten und dynamischem Wachstum im Thrombektomie-Segment
Der US-Konzern Penumbra (hat sich auf die Entwicklung innovativer Produkte zur Behandlung von neurovaskulären und peripheren Gefäßerkrankungen sowie Herz- und…
Stock Market Triggers This Bullish Upgrade; Google Jumps On Earnings Late
CrowdStrike and Penumbra are breakout stocks to watch Thursday.…
Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript
…
Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but…
Penumbra director Arani sells $3.45 million in stock By Investing.com
Penumbra director Arani sells $3.45 million in stock…
Penumbra im Pivotal-Point-Check: Innovativer Medizintechnikhersteller überzeugt mit starkem Thrombektomiegeschäft - UBS mit Kaufempfehlung nach Q4-Zahlen!
Das US-Thrombektomiegeschäft verzeichnete im 4. Quartal mit einem Anstieg von 27,3 % im Vergleich zum Vorjahr ein deutliches Wachstum.…
Penumbra überzeugt mit Marktanteilsgewinnen bei computergestützter Thrombektomie - Aktie mit neuem Jahreshoch!
Penumbra (PEN) hat sich als Medizintechnikunternehmen auf die minimalinvasive Behandlung von neurovaskulären und peripheren Gefäßerkrankungen spezialisiert. Der US-Markt ist für…
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript
…
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.…
Heres What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but…
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Penumbra stock rises following Strykers Inari Medical acquisition By Investing.com
Penumbra stock rises following Strykers Inari Medical acquisition…
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
PEN stays on investors radars due to its robust portfolio expansion and international growth plans.…
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
…
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbras U.S. thrombectomy business.…
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analysts bullish move, combined to put some zip in the companys shares.…
Why Penumbra Stock Zoomed Nearly 5% Higher Today
The company might just be the right kind of business operating at the right time in history.…
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.…
Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript
…
Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
Penumbras (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.…
Penumbras (PEN) New Launch to Enhance Blood Clot Removal
Penumbras (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.…
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
Penumbra (PEN) expects to materially increase both revenues and profitability in the companys international business in the next three years…